Action PGEN PRECIGEN, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Precigen, Inc.

Actions

PGEN

US74017N1054

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
1,58 USD +4,64 % Graphique intraday de Precigen, Inc. +2,60 % +17,91 %
04/06 Transcript : Precigen, Inc. - Special Call
03/06 PRECIGEN, INC. : Stifel Nicolaus optimiste sur le dossier ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Precigen Share Rise After Recurrent Respiratory Papillomatosis Study Shows 51% of Patients Surgery Free
Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response
Precigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $1.1M, vs. Street Est of $1.5M
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
North American Morning Briefing : Tech in Focus on -2-
Precigen Shares Fall After Downgrade From JPMorgan
Precigen Reports Full Year 2023 Financial Results and Business Updates
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
North American Morning Briefing : Stock Futures -2-
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
Precigen Highlights Pipeline Updates to be presented at the 42nd Annual J.P. Morgan Healthcare Conference
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PGEN
  4. Actualités Precigen, Inc.
  5. Autres langues